There is also increasing evidence for lineage plasticity between adenocarcinoma and neuroendocrine phenotypes in metastatic prostate cancer, induced upon anti-androgen therapy and partially reversed through epigenetic interventions such as EZH2 inhibition [43–45]. The gene discussed is EZH2; the disease is metastatic prostate carcinoma.